Insulin Glargine News and Research

RSS
Amylin and Lilly terminate exenatide alliance, resolve litigation

Amylin and Lilly terminate exenatide alliance, resolve litigation

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Byetta combination with insulin glargine gets FDA nod in type 2 diabetes

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Lantus initiation may help limit weight gain in type 2 diabetes patients

Lantus initiation may help limit weight gain in type 2 diabetes patients

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Novo Nordisk first quarter net profit increases 23% to DKK 4,073 million

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Amylin, Lilly submit BYETTA sNDA for type 2 diabetes

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Biodel reports data on Linjeta formulation for type 1 diabetes at Technology Meeting in Bethesda

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Access submits additional patent applications for Cobalamin-mediated oral drug delivery technology

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

Biocon, Pfizer enter global agreement to commercialize Insulin analog products

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

sanofi-aventis announces top-line results from lixisenatide Phase III GETGOAL-L-ASIA trial for Type-2 Diabetes

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Sanofi-aventis releases Lantus(R) study results for type 2 diabetes

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Amylin reports $164.4M total revenue for quarter ended June 30, 2010

Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate

Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Amylin presents improved indices of beta-cell function after three years of BYETTA(R) therapy

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

Lantus and Apidra improve outcomes, decrease glycemic variability: Study

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA

Final results of VIAject vs. RHI Phase 3 study in type 2 diabetes patients presented at 70th ADA